NASDAQ:CFRX - ContraFect Corporation
$0.54
 $-0.05
-8.63%
4:00PM EDT
2019-04-18
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CFRX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 03   199. 07   233. 87  
42 stocks rank:  4. 38 K 1. 43 K 1. 06 K
# analyst opinions:  3. 00   14. 48   14. 09  
mean recommendation:  1. 50   2. 09   2. 01  

quick ratio:  5. 29   5. 29   1. 92  
current ratio:  5. 42   5. 64   2. 40  

target price low:  0. 69   84. 50   115. 74  
target price avg:  1. 11   110. 73   137. 39  
target price high:  1. 50   136. 41   157. 80  
1-yr high:  2. 82   114. 11   138. 85  
last close:  0. 54   87. 56   116. 78  
50-day avg:  0. 45   95. 43   123. 53  
200-day avg:  1. 47   94. 13   121. 20  
1-yr low:  0. 36   72. 67   98. 41  
volume:  1. 81 M 2. 43 M 4. 85 M
50-day avg volume:  1. 38 M 2. 72 M 4. 97 M
200-day avg volume:  654. 60 K 2. 90 M 4. 58 M

1-day return:  -8. 47 % -0. 40 % 0. 07 %
this week return:  -8. 16 % -5. 72 % -4. 11 %
12-wk return:  3. 85 % 1. 78 % -0. 04 %
52-wk return:  -62. 13 % 10. 81 % 14. 09 %

enterprise value (EV):  16. 24 M 51. 19 B 117. 96 B
market cap:  42. 81 M 43. 00 B 104. 52 B
EBITDA:  -30. 97 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 52   4. 34   13. 27  
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -37. 68 M 2. 20 B 4. 21 B

shares outstanding:  79. 41 M 570. 91 M 1. 24 B
shares:  50. 78 M 571. 02 M 1. 23 B
shares short:  429. 76 K 9. 93 M 16. 79 M
shares short prior month:  553. 73 K 9. 96 M 16. 58 M
short ratio:  0. 90   5. 31   3. 30  
short % of float:  0. 61 % 5. 81 % 2. 61 %
total cash/share:  0. 38   11. 13   9. 30  
total cash:  30. 45 M 6. 70 B 7. 10 B
free cash flow:  -15. 64 M 3. 58 B 4. 74 B
operating cash flow:  -26. 26 M 4. 14 B 6. 32 B

book value:  0. 07   12. 76   26. 84  
price/book:  7. 71   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -54. 95 % --- ---
1-yr mean volatility:  -0. 17 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 49   2. 39   4. 08  
forward EPS:  -0. 44   3. 97   7. 14  
P/E:  -1. 09   13. 59   22. 83  
forward P/E:  -1. 34   -20. 05   14. 49  
PE/G:  0. 03   -1. 46   1. 68  
growth:  -36. 99 % 126. 81 % 29. 29 %
earnings high:  -0. 09   1. 02   1. 63  
earnings avg:  -0. 10   0. 76   1. 51  
earnings low:  -0. 11   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -46. 84 % -2. 80 % 5. 29 %
return on equity:  -205. 17 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  0. 25   1. 24   0. 93  
sharpe (1yr):  -0. 39   0. 29   0. 60  

held % insiders:  7. 63 % 6. 38 % 3. 38 %
held % institutions:  55. 70 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CFRX
.     + 0.24 =          0.24 :: INITIAL WEIGHT
.   + 23.379 =        23.619 :: spline projection addition
.    x 1.432 =        33.823 :: industry recommendation factor
.    x 2.536 =         85.78 :: symbol recommendation factor
.    x 0.995 =        85.379 :: return on assets factor
.    x 0.979 =        83.627 :: return on equity factor
.    x 2.962 =         247.7 :: current ratio factor
.     x 1.11 =        275.07 :: quick ratio factor
.    x 1.493 =       410.559 :: short ratio factor
.    x 2.158 =       885.836 :: price-to-book factor
.    x 1.286 =       1139.11 :: 5-day avg > 50-day avg
.    x 2.159 =      2459.258 :: P/E weight
.    x 2.209 =        5432.4 :: PE/G factor
.    x 1.485 =      8067.515 :: beta factor
.    x 0.395 =      3183.069 :: sharpe factor
.    x 1.552 =      4940.219 :: target low factor
.    x 1.344 =      6638.134 :: target mean factor
.    x 1.133 =      7523.218 :: target high factor
.    x 1.312 =      9867.817 :: industry 2-weeks return factor
.    x 0.969 =      9560.318 :: "drift" penalty 2 days ago
.    x 0.818 =      7817.725 :: "drift" penalty 3 days ago
.    x 0.858 =      6707.457 :: "drift" penalty 5 days ago
.    x 0.905 =      6067.453 :: overall "drift" factor
.    x 0.998 =      6052.958 :: largest single-day jump factor
.     x 0.06 =       363.759 :: low price factor
.      x 1.0 =       363.701 :: factor hist industry gain for week 15
.   cubeRoot =         7.138 :: reduced to standardize
.   - 28.117 =          0.03 :: add/subtract for performance
.                       0.03 :: FINAL WEIGHT for NASDAQ:CFRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org